HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care, announced it will host a conference call on Thursday, Nov. 12, 2026, at 4:30 p.m. ET to discuss financial results for the third quarter ended Sept. 30, 2026. Management will also provide updates on recent achievements, including results from the ALIGN-ACS pilot study, and upcoming milestones for the company’s Heart Attack Detection program. A press release detailing the quarterly results will be issued before the call.
Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, Ph.D., and Chief Financial Officer Timothy Cruickshank will host the call, followed by a question-and-answer session. Participants can access the conference by dialing 1-877-704-4453 domestically or 1-201-389-0920 internationally using conference code 13763268. A webcast and accompanying presentation will be available, with a telephone replay accessible approximately three hours after the call through Nov. 26, 2026.
To view the full press release, visit https://ibn.fm/QEwx4
About HeartBeam, Inc.
HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 2025(1) . The Company holds over 20 issued patents related to technology enablement.
NOTE TO INVESTORS: The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT
(1)Cleared Indications for Use
The HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025.
Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.
About MissionIR
MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.
MIR is where breaking news, insightful content and actionable information converge.
For more information, please visit www.MissionIR.com
Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer
MissionIRAustin, Texaswww.MissionIR.com512.354.7000 OfficeEditor@MissionIR.com
MissionIR is powered by IBN
